BlossomHill Therapeutics (NASDAQ:BLSM) Releases Quarterly Earnings Results, Misses Expectations By $0.36 EPS

BlossomHill Therapeutics (NASDAQ:BLSM) announced its quarterly earnings results on Thursday. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.36), FiscalAI reports.

BlossomHill Therapeutics Trading Down 5.5%

NASDAQ:BLSM traded down $0.81 on Friday, reaching $14.03. The stock had a trading volume of 18,473 shares, compared to its average volume of 200,450. The stock has a market cap of $445.87 million and a P/E ratio of -1.60. The stock’s fifty day simple moving average is $18.13. BlossomHill Therapeutics has a 12-month low of $11.02 and a 12-month high of $27.99.

Wall Street Analyst Weigh In

BLSM has been the subject of several research reports. Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. Leerink Partners upped their target price on BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of BlossomHill Therapeutics in a research report on Wednesday, September 30th. Guggenheim lifted their price target on BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Finally, JPMorgan Chase & Co. initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

About BlossomHill Therapeutics

BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.